{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-035239","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.805870+00:00","generated_at":"2026-06-10T05:32:03.750527+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evofem raises $1.5M via $2.88M convertible notes with warrants at $0.13 strike","bullets":["Issued $2,884,615 principal of 8% senior subordinate convertible notes due Sept 2026, convertible at $0.13/share.","Sold at 65% of face value; net proceeds approximately $1.5 million after offering costs.","Warrants: Series A (22.2M shares at $0.13) and prepaid Series B (4.8M shares at $0.001 after $0.129 prepayment).","Beneficial ownership blocker set at 4.99%; company must file registration statement within 90 days.","Covenants restrict additional debt, liens, dividends, and require auditor registered with PCAOB."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-035239","json":"https://secwatch.observer/filing/0001493152-23-035239.json","markdown":"https://secwatch.observer/filing/0001493152-23-035239.md","text":"https://secwatch.observer/filing/0001493152-23-035239.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223035239/0001493152-23-035239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223035239/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T05:32:03.750527+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5951528a02491cc494da6a934671795463447d55","claim":"Evofem Biosciences, Inc. entered into Securities Purchase Agreement with certain investors valued at Aggregate principal amount of $2,884,615 of senior subordinate convertible notes, Series A Warrants (effective 2023-09-27).","evidence_excerpt":"On September 27, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (“ SPA ”), with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $2,884,615 (the “ Notes ”), warrants to purchase an aggregate of 22,189,349 shares (the “ Series A Warrants ”) of common stock the Company, par value $0.0001 (the “Common Stock”), and prepaid warrants to purchase an aggregate of 4,807,692 shares of Common Stock (the “ Series B Warrants ,” and, together with the Series A Warrants, the “ Warrants ”) (collectively, the “ Offering ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223035239/0001493152-23-035239-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"Aggregate principal amount of $2,884,615 of senior subordinate convertible notes, Series A Warrants"},{"label":"Effective","value":"2023-09-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}